Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 17/100

Termination Rate

0.0%

0 terminated out of 19 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

53%

10 trials in Phase 3/4

Results Transparency

64%

9 of 14 completed with results

Key Signals

9 with results100% success

Data Visualizations

Phase Distribution

16Total
Not Applicable (3)
Early P 1 (1)
P 2 (2)
P 3 (10)

Trial Status

Completed14
Not Yet Recruiting2
Enrolling By Invitation1
Withdrawn1
Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 14 completed trials

Clinical Trials (19)

Showing 19 of 19 trials
NCT06884280Phase 3Recruiting

Comparing High and Low Dose Iron Treatments for People on Peritoneal Dialysis: The PALaDIN Study

NCT05990166Phase 2Completed

Assessing the Effect of a Mineral-enriched Powder on Iron Deficiency in Women of Reproductive Age

NCT07197424Not ApplicableNot Yet RecruitingPrimary

The Use of Robot Assisted Magnetically Controlled Capsule Endoscopy in Patients With Iron Deficiency Anaemia

NCT06276140Enrolling By Invitation

Iron-deficiency Anaemia and Its Impact on Recovery After Colorectal Cancer Surgery

NCT06761352Not Yet RecruitingPrimary

Questionnaire About Risk Factors of Iron Deficiency Anemia in Pregnancy

NCT04968379Phase 2WithdrawnPrimary

Safety, Tolerability, PK and PD of Intravenous Ferric Carboxymaltose in Infants With Iron Deficiency Anemia

NCT01340872Phase 3CompletedPrimary

Safety and Efficacy Study of Oral Ferric Iron To Treat Iron Deficiency Anaemia in Quiescent Ulcerative Colitis (AEGIS-1)

NCT01352221Phase 3CompletedPrimary

Safety and Efficacy Study of Oral Ferric Iron To Treat Iron Deficiency Anaemia in Quiescent Crohn's Disease (AEGIS-2)

NCT02940886Phase 3CompletedPrimary

Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for the Treatment of Iron Deficiency Anemia (IDA)

NCT02940860Phase 3CompletedPrimary

Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for Treatment of Iron Deficiency Anemia in Non-Dialysis-Dependent Chronic Kidney Disease

NCT02962648Phase 3Completed

An Extension Trial to Assess the Safety of Re-dosing of Iron Isomaltoside/Ferric Derisomaltose (Monofer®/Monoferric®)

NCT03237065Phase 3CompletedPrimary

Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose or Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia

NCT03238911Phase 3CompletedPrimary

Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia

NCT02546154CompletedPrimary

Time to Relapse of Iron Deficiency Anaemia After Standard Treatment With The Intravenous Iron (Monofer®)

NCT02130063Phase 3CompletedPrimary

IDA-01 A Randomised, Open-Label, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) and Iron Sucrose

NCT02965209Not ApplicableCompleted

European Novel Motorized Spiral Endoscopy Trial

NCT01878734Not ApplicableCompletedPrimary

Zambia Micronutrient Powder Trial Effectiveness Study

NCT00994318Phase 3CompletedPrimary

Ferric Carboxymaltose (FCM) Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)

NCT01991600Early Phase 1CompletedPrimary

A Pilot Study to Assess the Influence of Dietary Organic Acids on Iron Absorption.

Showing all 19 trials

Research Network

Activity Timeline